Guinea-Bissau vs Kyrgyzstan: The number of people with susceptibility test result for rifampicin
Guinea-Bissau
1,934
in 2021
Kyrgyzstan
1,932
in 2021
Guinea-Bissau rank
48th
Kyrgyzstan rank
49th
The number of people with susceptibility test result for rifampicin over time
- Guinea-Bissau
- Kyrgyzstan
How they compare
Guinea-Bissau currently reports 1,934 against 1,932 in Kyrgyzstan, a difference of 2.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was Kyrgyzstan ahead.
Guinea-Bissau ranks 48th and Kyrgyzstan ranks 49th of 155 countries.
Kyrgyzstan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guinea-Bissau | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.67 | 2,316 | 2,295 | Kyrgyzstan |
| 2020s | 1,573 | 1,836 | 263.5 | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Guinea-Bissau or Kyrgyzstan?
- Guinea-Bissau, at 1,934 against 1,932 in Kyrgyzstan as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Guinea-Bissau and Kyrgyzstan?
- 2, with Guinea-Bissau ahead.
- How many years of comparable data are there for Guinea-Bissau and Kyrgyzstan?
- 5 years are reported by both, from 2017 to 2021.
- How do Guinea-Bissau and Kyrgyzstan rank globally for the number of people with susceptibility test result for rifampicin?
- Guinea-Bissau ranks 48th and Kyrgyzstan ranks 49th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.